Trial Profile
A phase I/II, open-label study of safety, immune activation and efficacy of histamine dihydrochloride and low-dose interleukin-2 in adult tyrosine kinase inhibitor-treated patients with chronic myeloid leukemia
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 20 Nov 2017
Price :
$35
*
At a glance
- Drugs Aldesleukin (Primary) ; Histamine dihydrochloride (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 20 Nov 2017 New trial record